The rise of allergies in the last three decades, particularly allergic asthma and food allergies, has posed a significant public health challenge, affecting over 220 million individuals globally. As the scientific community delves deeper into the complexities of these conditions, Genoskin is proud to present its 6th episode of the Naked Immunology webinar series, focusing on innovative therapeutic approaches to allergic diseases.
When? October 12th, 8am PT | 11am ET | 5pm CET
Where? Register Here
Titled “Development of Vaccines for the Treatment of Allergic Diseases”, this webinar will spotlight cutting-edge research centered on conjugate vaccines called “kinoids”. These revolutionary vaccines show potential for neutralizing antibody responses against IL-4, IL-13, and IgE, resulting in lasting protection in models of allergic asthma and anaphylaxis. The implications of such findings could transform the landscape of allergic disease treatments, providing a long-lasting solution compared to the currently available therapeutic antibodies.
About the Speaker
The esteemed Dr. Laurent Reber is the Laboratory Director at the Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy, France) and Principal Investigator at the French INSERM, his accolades also include his role as Director of Research and Innovation at NEOVACS (France). Dr. Reber’s illustrious career has been marked by notable contributions to the field of asthma and allergy. Having obtained his PhD in Immunology from the University of Strasbourg and furthering his post-doctoral studies at Stanford University under Dr. Stephen Galli, his dedication to the translation of research into diagnostic tools and therapeutic strategies is evident.
Connect and Explore
For more immunology knowledge sharing, take a look at the Naked Immunology webinar series.
Don’t miss out on this enlightening session, one that promises to be a confluence of path-breaking research and practical insights. Reserve your spot today and be a part of the conversation shaping the future of allergic disease treatments.